ECSP23088864A - Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso - Google Patents
Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de usoInfo
- Publication number
- ECSP23088864A ECSP23088864A ECSENADI202388864A ECDI202388864A ECSP23088864A EC SP23088864 A ECSP23088864 A EC SP23088864A EC SENADI202388864 A ECSENADI202388864 A EC SENADI202388864A EC DI202388864 A ECDI202388864 A EC DI202388864A EC SP23088864 A ECSP23088864 A EC SP23088864A
- Authority
- EC
- Ecuador
- Prior art keywords
- difluoropropanamide
- methods
- polymorphic forms
- derivatives
- methyl bardoxolone
- Prior art date
Links
- XJGBNZRVGOENRN-UHFFFAOYSA-N 2,2-difluoropropanamide Chemical class CC(F)(F)C(N)=O XJGBNZRVGOENRN-UHFFFAOYSA-N 0.000 title 1
- TXGZJQLMVSIZEI-UQMAOPSPSA-N Bardoxolone Chemical compound C1=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5[C@H]4C(=O)C=C3[C@]21C TXGZJQLMVSIZEI-UQMAOPSPSA-N 0.000 title 1
- 229950002483 bardoxolone Drugs 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se relaciona en general con el compuesto: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-ciano-2,2,6a,6b,9,9, 12a-heptametil-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a, 14b-octadecahidropiren-4a-il)-2,2-difluoropropanamida, formas polimórficas del mismo, métodos para su preparación y uso, composiciones farmacéuticas del mismo y conjuntos de elementos y artículos para elaborarlo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361815502P | 2013-04-24 | 2013-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23088864A true ECSP23088864A (es) | 2023-12-29 |
Family
ID=50842351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202388864A ECSP23088864A (es) | 2013-04-24 | 2023-11-23 | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US9856286B2 (es) |
| EP (2) | EP2989114B1 (es) |
| JP (2) | JP6409050B2 (es) |
| KR (2) | KR102342915B1 (es) |
| CN (1) | CN105324389B (es) |
| AR (1) | AR096046A1 (es) |
| AU (2) | AU2014257072C1 (es) |
| BR (1) | BR112015027012B1 (es) |
| CA (1) | CA2909066C (es) |
| CL (1) | CL2015003135A1 (es) |
| CR (1) | CR20150620A (es) |
| CY (1) | CY1120570T1 (es) |
| DK (1) | DK2989114T3 (es) |
| DO (1) | DOP2015000263A (es) |
| EC (1) | ECSP23088864A (es) |
| ES (1) | ES2683626T3 (es) |
| HR (1) | HRP20181321T1 (es) |
| HU (1) | HUE039899T2 (es) |
| IL (1) | IL242183B (es) |
| LT (1) | LT2989114T (es) |
| MX (1) | MX372760B (es) |
| MY (1) | MY182677A (es) |
| PE (1) | PE20160006A1 (es) |
| PH (1) | PH12015502459B1 (es) |
| PL (1) | PL2989114T3 (es) |
| PT (1) | PT2989114T (es) |
| RS (1) | RS57571B1 (es) |
| RU (2) | RU2693833C2 (es) |
| SG (2) | SG10201805231WA (es) |
| SI (1) | SI2989114T1 (es) |
| TW (2) | TWI649330B (es) |
| UA (1) | UA118348C2 (es) |
| UY (2) | UY39092A (es) |
| WO (1) | WO2014176415A1 (es) |
| ZA (1) | ZA201507481B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101880692B1 (ko) | 2008-01-11 | 2018-07-20 | 리타 파마슈티컬스 잉크. | 합성 트리테르페노이드 및 질병 치료시의 사용 방법 |
| PT2276493T (pt) | 2008-04-18 | 2019-01-10 | Reata Pharmaceuticals Inc | Moduladores de inflamação anti-oxidantes: derivados de ácidos oleonucleicos com uma modificação no grupo aminno e outras modificações em c-17 |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| AR092823A1 (es) | 2012-04-27 | 2015-05-06 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimorficas y sus metodos de uso |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| HRP20191165T1 (hr) | 2012-09-10 | 2019-10-04 | Reata Pharmaceuticals, Inc. | C17-alkandiilni i alkendiilni derivati oleanolne kiseline i postupci njihove upotrebe |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| AU2016278040B2 (en) | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| CN106309451A (zh) * | 2016-08-14 | 2017-01-11 | 吴芊葭 | 一种头孢呋辛酯的药物组合物及其医药用途 |
| CN106279344A (zh) * | 2016-08-14 | 2017-01-04 | 吴芊葭 | 一种从防风中分离的天然化合物及其制备方法、医药应用 |
| MX2019005401A (es) | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
| US20190388407A1 (en) | 2017-02-12 | 2019-12-26 | Aiviva Biopharma, Inc. | Multikinase inhibitors of vegf and tfg beta and uses thereof |
| CN108558985B (zh) * | 2018-05-19 | 2019-06-07 | 河南省科学院高新技术研究中心 | 白桦脂酸衍生物及其合成方法和应用 |
| US12060340B2 (en) | 2018-06-20 | 2024-08-13 | Reata Pharmaceuticals, Inc | Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith |
| KR20240139087A (ko) * | 2018-08-15 | 2024-09-20 | 아이비바 바이오파마, 인크. | Vegf 및 tgf 베타의 다중 키나아제 억제제 및 이의 용도 |
| KR102753167B1 (ko) | 2018-08-20 | 2025-01-09 | 얀센 파마슈티카 엔브이 | KEAP1-Nrf2 단백질간 상호작용 억제제 |
| WO2020190733A1 (en) * | 2019-03-15 | 2020-09-24 | University Of Rhode Island Board Of Trustees | pHLIP®-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASED TISSUE |
| WO2020226201A1 (ko) * | 2019-05-08 | 2020-11-12 | 경상대학교병원 | 피부 저색소증 예방 또는 치료용 약학적 조성물, 건강기능식품 및 화장료 조성물 |
| JP7695229B2 (ja) | 2019-07-19 | 2025-06-18 | リアタ ファーマシューティカルズ インコーポレイテッド | Ｃ１７極性置換ヘテロ芳香族合成トリテルペノイドおよびその使用方法 |
| AU2020405181A1 (en) * | 2019-12-19 | 2022-07-14 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids with nitrogen-based substituents at C-17 and methods of use thereof |
| US20240293351A1 (en) * | 2020-12-11 | 2024-09-05 | Reata Pharmaceuticals Holdings, LLC | Methods of administering synthetic triterpenoids |
| JP2024504637A (ja) * | 2021-01-18 | 2024-02-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 合成ウルソール酸誘導体及びその使用方法 |
| CN113197905B (zh) * | 2021-04-23 | 2022-04-19 | 浙江大学 | 三萜类化合物在制备神经母细胞瘤治疗药物中的应用 |
| CN114344308A (zh) * | 2021-12-22 | 2022-04-15 | 山西医科大学第二医院 | 甲基巴多索隆在制备防治骨关节炎的药物中的应用 |
| EP4446312A4 (en) | 2022-01-07 | 2025-11-19 | Chugai Pharmaceutical Co Ltd | HETEROCYCLIC NITROGEN-CONTAINING COMPOUND HAVING AN NRF2-ACTIVATING EFFECT |
| US20240124393A1 (en) * | 2022-09-21 | 2024-04-18 | Sicor - Societa Italiana Corticosteroidi S.R.L. | Process and intermediates for preparation of omaveloxolone and salts thereof |
| WO2024262491A1 (ja) | 2023-06-19 | 2024-12-26 | 中外製薬株式会社 | Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| CA2424013A1 (en) | 2000-09-29 | 2002-04-04 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
| US6689767B2 (en) | 2000-09-29 | 2004-02-10 | Regents Of The University Of Minnesota | Triterpenes having antibacterial activity |
| WO2002047611A2 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| DK1465615T3 (da) | 2002-01-15 | 2012-11-12 | Dartmouth College | Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf |
| CA2473799A1 (en) | 2002-01-18 | 2003-07-31 | Regents Of The University Of Minnesota | Triterpene quaternary salts as biologically active surfactants |
| JP2006515859A (ja) | 2002-05-13 | 2006-06-08 | トラスティーズ オブ ダートマス カレッジ | 阻害剤およびその使用法 |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| EP1959969A2 (en) | 2005-07-01 | 2008-08-27 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| EP1996205A2 (en) | 2006-03-23 | 2008-12-03 | Advanced Life Sciences Inc. | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin |
| WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| US7714012B2 (en) | 2006-11-17 | 2010-05-11 | Trustees Of Dartmouth University | Synthesis and biological activities of new tricyclic-bis-enones (TBEs) |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US20080254055A1 (en) | 2007-04-11 | 2008-10-16 | John Erich Oblong | Compositions for Regulation of Hair Growth |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| US20090048205A1 (en) | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
| KR101880692B1 (ko) | 2008-01-11 | 2018-07-20 | 리타 파마슈티컬스 잉크. | 합성 트리테르페노이드 및 질병 치료시의 사용 방법 |
| WO2009146218A2 (en) | 2008-04-18 | 2009-12-03 | Reata Pharmaceuticals, Inc. | Compounds including an anti-inflammatory pharmacore and methods of use |
| TW201004627A (en) | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| PT2276493T (pt) | 2008-04-18 | 2019-01-10 | Reata Pharmaceuticals Inc | Moduladores de inflamação anti-oxidantes: derivados de ácidos oleonucleicos com uma modificação no grupo aminno e outras modificações em c-17 |
| MX2010011437A (es) | 2008-04-18 | 2010-12-20 | Reata Pharmaceuticals Inc | Moduladores antioxidantes de inflamacion: derivados del acido oleanolico con saturacion en el anillo c. |
| ES2613964T3 (es) | 2008-04-18 | 2017-05-29 | Reata Pharmaceuticals, Inc. | Moduladores de inflamación antioxidantes: Derivados de ácido oleanólico homologado C-17 |
| JP5758801B2 (ja) | 2008-07-22 | 2015-08-05 | トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ | 単環式シアノエノンおよびその使用方法説明 |
| WO2010053817A1 (en) | 2008-11-04 | 2010-05-14 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| PT3254675T (pt) | 2009-02-13 | 2019-06-14 | Reata Pharmaceuticals Inc | Composições de dosagem oral de libertação prolongada que contêm cddo-me amorfo |
| WO2010127029A1 (en) | 2009-05-01 | 2010-11-04 | Ophthotech Corporation | Methods for treating or preventing ophthalmological diseases |
| SI2558105T1 (sl) | 2010-04-12 | 2020-02-28 | Reata Pharmaceuticals, Inc. | Bardoksolon metil za zdravljenje debelosti |
| WO2012009171A2 (en) | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| RS56795B1 (sr) | 2010-12-17 | 2018-04-30 | Reata Pharmaceuticals Inc | Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije |
| KR101956399B1 (ko) * | 2011-03-11 | 2019-03-08 | 리아타 파마슈티컬즈, 아이엔씨. | Ｃ４모노메틸 트리터페노이드 유도체 및 그의 이용 방법 |
| WO2012154554A1 (en) | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid triterpene derivatives and their uses |
| AR092823A1 (es) | 2012-04-27 | 2015-05-06 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimorficas y sus metodos de uso |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| WO2013169740A2 (en) | 2012-05-08 | 2013-11-14 | Trustees Of Dartmouth College | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| EP2892910B1 (en) | 2012-09-10 | 2016-09-07 | AbbVie Inc. | Glycyrrhetinic acid derivatives with anti-inflammatory activity |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| MX366954B (es) | 2012-09-10 | 2019-07-31 | Reata Pharmaceuticals Inc | Derivados de c17-heteroarilo de ácido oleanólico y métodos de uso de los mismos. |
| HRP20191165T1 (hr) | 2012-09-10 | 2019-10-04 | Reata Pharmaceuticals, Inc. | C17-alkandiilni i alkendiilni derivati oleanolne kiseline i postupci njihove upotrebe |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| BR112016003454B1 (pt) | 2013-08-23 | 2023-02-14 | Reata Pharmaceuticals, Inc. | Uso de composto de metil bardoxolona |
| CA2936550C (en) | 2014-01-24 | 2022-07-26 | Abbvie Inc. | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| KR20240035818A (ko) | 2015-02-12 | 2024-03-18 | 리아타 파마슈티컬즈, 아이엔씨. | 항산화 염증 조절제로서의 이미다졸릴 트리사이클릭 에논 |
| CA2998681C (en) | 2015-09-23 | 2024-02-06 | Reata Pharmaceuticals, Inc. | C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses |
| MX2019005401A (es) | 2016-11-08 | 2019-08-05 | Reata Pharmaceuticals Inc | Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma. |
-
2014
- 2014-04-21 TW TW103114431A patent/TWI649330B/zh active
- 2014-04-21 AR ARP140101652A patent/AR096046A1/es unknown
- 2014-04-21 UY UY0001039092A patent/UY39092A/es not_active Application Discontinuation
- 2014-04-21 UY UY0001035534A patent/UY35534A/es active IP Right Grant
- 2014-04-21 TW TW107147785A patent/TW201936625A/zh unknown
- 2014-04-24 HU HUE14727306A patent/HUE039899T2/hu unknown
- 2014-04-24 RU RU2015150069A patent/RU2693833C2/ru active
- 2014-04-24 BR BR112015027012-3A patent/BR112015027012B1/pt active IP Right Grant
- 2014-04-24 SG SG10201805231WA patent/SG10201805231WA/en unknown
- 2014-04-24 JP JP2016510780A patent/JP6409050B2/ja active Active
- 2014-04-24 PT PT14727306T patent/PT2989114T/pt unknown
- 2014-04-24 AU AU2014257072A patent/AU2014257072C1/en active Active
- 2014-04-24 ES ES14727306.4T patent/ES2683626T3/es active Active
- 2014-04-24 PE PE2015002271A patent/PE20160006A1/es unknown
- 2014-04-24 DK DK14727306.4T patent/DK2989114T3/en active
- 2014-04-24 CA CA2909066A patent/CA2909066C/en active Active
- 2014-04-24 SG SG11201508752WA patent/SG11201508752WA/en unknown
- 2014-04-24 CN CN201480035822.1A patent/CN105324389B/zh active Active
- 2014-04-24 LT LTEP14727306.4T patent/LT2989114T/lt unknown
- 2014-04-24 UA UAA201511559A patent/UA118348C2/uk unknown
- 2014-04-24 EP EP14727306.4A patent/EP2989114B1/en active Active
- 2014-04-24 MX MX2015014792A patent/MX372760B/es active IP Right Grant
- 2014-04-24 HR HRP20181321TT patent/HRP20181321T1/hr unknown
- 2014-04-24 US US14/260,532 patent/US9856286B2/en active Active
- 2014-04-24 RS RS20180945A patent/RS57571B1/sr unknown
- 2014-04-24 RU RU2019120236A patent/RU2019120236A/ru not_active Application Discontinuation
- 2014-04-24 MY MYPI2015703682A patent/MY182677A/en unknown
- 2014-04-24 EP EP18170879.3A patent/EP3453715A1/en not_active Withdrawn
- 2014-04-24 PL PL14727306T patent/PL2989114T3/pl unknown
- 2014-04-24 WO PCT/US2014/035279 patent/WO2014176415A1/en not_active Ceased
- 2014-04-24 SI SI201430835T patent/SI2989114T1/sl unknown
- 2014-04-24 KR KR1020217003976A patent/KR102342915B1/ko active Active
- 2014-04-24 KR KR1020157033427A patent/KR20150144807A/ko not_active Withdrawn
-
2015
- 2015-10-08 ZA ZA2015/07481A patent/ZA201507481B/en unknown
- 2015-10-16 DO DO2015000263A patent/DOP2015000263A/es unknown
- 2015-10-20 IL IL24218315A patent/IL242183B/en active IP Right Grant
- 2015-10-23 CL CL2015003135A patent/CL2015003135A1/es unknown
- 2015-10-23 PH PH12015502459A patent/PH12015502459B1/en unknown
- 2015-11-20 CR CR20150620A patent/CR20150620A/es unknown
-
2017
- 2017-11-22 US US15/821,508 patent/US20180094020A1/en not_active Abandoned
-
2018
- 2018-08-10 CY CY20181100837T patent/CY1120570T1/el unknown
- 2018-09-20 JP JP2018175962A patent/JP2019023200A/ja active Pending
- 2018-11-09 US US16/186,051 patent/US11117927B2/en active Active
-
2019
- 2019-01-18 AU AU2019200341A patent/AU2019200341A1/en not_active Abandoned
-
2021
- 2021-08-06 US US17/444,594 patent/US11873320B2/en active Active
-
2023
- 2023-11-23 EC ECSENADI202388864A patent/ECSP23088864A/es unknown
-
2024
- 2024-01-12 US US18/411,501 patent/US12384815B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP23088864A (es) | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso | |
| DOP2014000236A (es) | Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos | |
| DOP2017000176A (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| UY36737A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| CL2015003357A1 (es) | Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| BR112016001876A2 (pt) | composto de benzoxaborol tricíclico, método de preparação e uso do mesmo | |
| BR112017004000A2 (pt) | formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida | |
| BR112016028083A2 (pt) | Composição oral farmacêutica de isotretinoina e seu processo de preparação | |
| BR112015030589A8 (pt) | formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas | |
| AR124675A2 (es) | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso | |
| PY1407085A (es) | Formas cristalinas de un inhibidor de la propil hidroxilasa | |
| UY35347A (es) | Formas cristalinas de un inhibidor de la prolil hidroxilasa |